{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002893","form_type":"8-K","ticker":"AGPU","cik":"0001446159","company_name":"Axe Compute Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.454880+00:00","generated_at":"2026-06-01T22:52:14.722288+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Predictive Oncology Q1 net loss $4.2M on revenue $0.4M; cash $5.2M, EPS -$1.04","bullets":["Net loss of ~$4.2M, wider than $3.5M loss in Q1 2023; diluted EPS -$1.04 vs -$0.86.","Revenue $419,646, up 75% YoY from $239,895, driven by STREAMWAY system sales.","Cash $5.2M at March 31, 2024, down from $8.7M at Dec 31, 2023.","Abstract accepted at ASCO 2024 for ovarian cancer machine-learning survival model; collaboration with Fujifilm on endotoxin testing announced.","FluGen collaboration for intranasal flu vaccine under $6.2M DoD grant progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002893","json":"https://secwatch.observer/filing/0001171843-24-002893.json","markdown":"https://secwatch.observer/filing/0001171843-24-002893.md","text":"https://secwatch.observer/filing/0001171843-24-002893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/0001171843-24-002893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/f8k_051424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:52:14.722288+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"844d6cb5b548f50ca173cb381cca233b214487de","claim":"Axe Compute Inc. reported the quarter ended March 31, 2024 results: revenue $419,646, net income net loss of approximately $4.2 million, EPS $(1.04).","evidence_excerpt":"share for the quarter ended March 31, 2024, was $(1.04), compared to $(0.86) for the quarter ended March 31, 2023. Q1 2024 Financial Results: The company recorded revenue of $419,646 for the first quarter of 2024, compared to $239,895 for the comparable period in 2023. Revenues for the quarter ended March 31, 2024, and March 31, 2023, were primarily derived","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446159/000117184324002893/0001171843-24-002893-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$419,646"},{"label":"Net income","value":"net loss of approximately $4.2 million"},{"label":"EPS","value":"$(1.04)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}